Marshall Fordyce, Director, President, and CEO, on April 14, 2026, sold 22,951 shares in Vera Therapeutics (VERA) for $1,011,051. Following the Form 4 filing with the SEC, Fordyce has control over a total of 457,274 Class A common shares of the company, with 235,244 shares held directly and 222,030 controlled indirectly.
SEC Filing:
Jorge Santos Da Silva, Director, Chief Executive Officer, on April 10, 2026, sold 150,000 shares in Moonlake Immunotherapeutics (MLTX) for $2,752,163. Following the Form 4 filing with the SEC, Da Silva has control over a total of 2,924,893 Class A ordinary shares of the company, with 2,924,893 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1821586/000121390026043647/xslF345X05/ownership.xml
John C.M. Farquhar, Director, Chief Executive Officer, on April 10, 2026, sold 22,562 shares in Heartflow (HTFL) for $602,857. Following the Form 4 filing with the SEC, Farquhar has control over a total of 549,163 common shares of the company, with 549,163 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000055/xslF345X05/form4.xml
Piyush B Sevalia, Executive Vice President, Chief Business Officer, on April 10, 2026, sold 1,247 shares in Sitime (SITM) for $529,975. Following the Form 4 filing with the SEC, Sevalia has control over a total of 86,669 common shares of the company, with 86,669 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1451809/000179075626000012/xslF345X05/wk-form4_1776203023.xml